IL27

Summary

IL27 (interleukin 27, HGNC:19157) is a protein-coding gene on chromosome 16p12.1-p11.2, encoding Interleukin-27 subunit alpha (Q8NEV9). Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity.

The protein encoded by this gene is one of the subunits of a heterodimeric cytokine complex. This protein is related to interleukin 12A (IL12A). It interacts with Epstein-Barr virus induced gene 3 (EBI3), a protein similar to interleukin 12B (IL12B), and forms a complex that has been shown to drive rapid expansion of naive but not memory CD4(+) T cells. The complex is also found to synergize strongly with interleukin 12 to trigger interferon gamma (IFNG) production of naive CD4(+) T cells. The biological effects of this cytokine are mediated by the class I cytokine receptor (WSX1/TCRR).

Source: NCBI Gene 246778 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 42 total — 1 pathogenic
• MANE Select transcript: NM_145659

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19157
Approved symbol	IL27
Name	interleukin 27
Location	16p12.1-p11.2
Locus type	gene with protein product
Status	Approved
Aliases	IL-27, p28, IL27p28, IL-27A, IL27A, MGC71873
Ensembl gene	ENSG00000197272
Ensembl biotype	protein_coding
OMIM	608273
Entrez	246778

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000356897, ENST00000568075

RefSeq mRNA: 1 — MANE Select: NM_145659 NM_145659

CCDS: CCDS10633

Canonical transcript exons

ENST00000356897 — 5 exons

Exon	Start	End
ENSE00001404109	28501976	28502134
ENSE00001417879	28499362	28499920
ENSE00001424649	28506781	28506834
ENSE00003473194	28503695	28503793
ENSE00003619615	28503878	28504050

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 87.87.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.9631 / max 309.5546, expressed in 106 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
156885	2.7743	106
207822	0.1889	53

Top tissues by expression

232 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	87.87	gold quality
monocyte	CL:0000576	74.95	gold quality
leukocyte	CL:0000738	74.43	gold quality
liver	UBERON:0002107	71.89	gold quality
granulocyte	CL:0000094	70.61	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	66.89	gold quality
apex of heart	UBERON:0002098	66.89	gold quality
blood	UBERON:0000178	64.99	gold quality
spleen	UBERON:0002106	63.47	gold quality
vermiform appendix	UBERON:0001154	59.23	gold quality
caecum	UBERON:0001153	55.05	gold quality
bone marrow cell	CL:0002092	54.81	gold quality
buccal mucosa cell	CL:0002336	54.28	gold quality
upper lobe of left lung	UBERON:0008952	52.95	gold quality
mucosa of transverse colon	UBERON:0004991	52.84	gold quality
upper lobe of lung	UBERON:0008948	51.36	gold quality
lymph node	UBERON:0000029	49.55	gold quality
sural nerve	UBERON:0015488	49.49	gold quality
bone marrow	UBERON:0002371	48.64	gold quality
left adrenal gland	UBERON:0001234	48.17	gold quality
right adrenal gland cortex	UBERON:0035827	47.43	gold quality
right lung	UBERON:0002167	47.42	gold quality
placenta	UBERON:0001987	47.30	gold quality
left adrenal gland cortex	UBERON:0035825	46.86	gold quality
adrenal cortex	UBERON:0001235	46.49	gold quality
right adrenal gland	UBERON:0001233	46.36	gold quality
lung	UBERON:0002048	45.77	gold quality
adrenal gland	UBERON:0002369	45.34	gold quality
omental fat pad	UBERON:0010414	45.05	gold quality
peritoneum	UBERON:0002358	45.04	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.11

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting IL27, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-148A-5P	99.30	68.27	1141
HSA-MIR-3168	99.08	67.75	1384
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-935	98.82	69.36	1072
HSA-MIR-6846-5P	98.81	65.86	1121
HSA-MIR-6848-5P	98.81	65.49	1126
HSA-MIR-4751	98.80	64.95	525
HSA-MIR-6867-3P	98.12	66.07	1305
HSA-MIR-4287	97.55	67.24	1247
HSA-MIR-4685-3P	97.55	67.35	1255
HSA-MIR-874-5P	96.93	63.92	1014
HSA-MIR-4509	96.19	65.80	900
HSA-MIR-4693-3P	95.23	65.92	735

Literature-anchored findings (GeneRIF, showing 40)

• an early product of activated antigen-presenting cells; drives rapid clonal expansion of naive but not memory CD4(+) T cells (PMID:12121660)
• IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms (PMID:14657353)
• IL-27 triggers STAT activation and gene transcription of a subset of inflammatory cytokines in primary human mast cells and in human monocytes. (PMID:14764690)
• EBI3 may play a role, independently from its association to p28, in regulating anti-viral or anti-tumoral immune responses (PMID:15793300)
• The B cell response to IL-27 is modulated during B cell differentiation and varies depending on the mode of B cell activation. (PMID:16670296)
• IL-23 and IL-17 have roles in inflammation [commentary] (PMID:16670765)
• IL-27 possesses potent antiangiogenic activity, which plays an important role in its antitumor and antimetastatic activities. (PMID:16751375)
• IL-27 was found to be a potent inhibitor of HIV-1 replication in peripheral blood mononuclear cells, CD4+ T cells, and macrophages (PMID:17068156)
• Our results strongly suggest that the g.-964A > G polymorphism of IL-27p28 is most likely associated with susceptibility to asthma. (PMID:17318299)
• IL-27p28 subunit was induced by IFN-beta alone or during LPS-induced maturation of dendritic cells in a type I IFN-dependent manner through IFN regulatory factor-1 activation. (PMID:17985330)
• findings indicate that the restricted Th1 responses in newborns owing to deficient IL-12 production may be compensated for, in part, by enhanced IL-27 secretion (PMID:18167155)
• Our data suggest that the pro-inflammatory role of IL-27 is mediated in part through increased expression of key molecules involved in the class II and class I MHC pathways. (PMID:18178151)
• this first demonstration that both MHC II and I expression are increased in endothelial cells after IL-27 stimulation suggests that IL-27 may be important in conferring immune function on vascular endothelium (PMID:18191724)
• IL-27 activates monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38 (PMID:18424756)
• IL-27 has an antiproliferative activity on melanomas through WSX-1/STAT1 signaling. (PMID:18453571)
• IL-27-mediated antitumour effects produced in a mature T cell-defective condition were attributable to enhanced interferon-gamma production and natural killer activities. (PMID:18482209)
• Data suggest that polymorphisms in the IL-27 gene may play a role in the development of chronic obstructive pulmonary disease in Chinese population. (PMID:18554158)
• These results implicate IL-12 and IL-27 in regulating human macrophages, and IL-27 derived from macrophages during infection impedes control of Mycobacterium tuberculosis growth. (PMID:18557702)
• The suppressive capacity of inducible regulatory T (Treg) cells is sustained with IL-27 and interferon (IFN)-gamma. (PMID:19124747)
• Single nucleotide polymorphisms in interleukin 27 is associated with nasopharyngeal carcinoma. (PMID:19148899)
• IL-27 down-regulates expression of T helper cell (Th)17-specific orphan nuclear receptor ROR gamma t and reduces production of IL-17A and IL-17F in naive T cells. (PMID:19380822)
• Both subunits of IL-27 were expressed in chronic lesional allergic eczematous skin, whereas the IL-27 subunit EBV-induced gene 3 was not detectable in the acute phase of eczema (PMID:19523673)
• Results reveal an IL-27-independent function of WSX1: sensitizing natural killer cell-mediated antitumor surveillance. (PMID:19549909)
• the IL-27-IFN-alpha connection is operative in CD4(+) T cells, consistent with an IFN-alpha-dependent pathway underlying host cell defense to HIV (PMID:19556424)
• exerts interferon-like functions in liver cells and can contribute to the antiviral response (PMID:19582813)
• Human IL-27 may act as an in vitro anti-inflammatory cytokine in human bone destruction by inhibiting osteoclastogenesis from granulocyte-macrophage colony-forming unit-producing cells via STAT1-dependent down-regulation of transcription factor c-Fos. (PMID:19620301)
• IL-27 plays a key role in human T cells by promoting a specific subset of IL-10-secreting regulatory T cells and inhibiting T helper (Th)17 cells, thus providing a dual regulatory mechanism to control autoimmunity and tissue inflammation. (PMID:19625647)
• IL27 were higher in affected areas compared to unaffected ones in Ulcerative Colitis but not Crohn Disease. (PMID:19657406)
• Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. (PMID:19686419)
• IL-12 and IL-27 have roles in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients (PMID:19798410)
• IL-27 may promote the onset of psoriasis, while it may simultaneously attenuate the expanded inflammation in this disease (PMID:19924133)
• in addition to its well-known antiinflammatory effects, IL-27 plays a homeostatic role in restraining bone erosion (PMID:20112358)
• The in vitro effects of IL-27, alone or in combination with inflammatory cytokine tumor necrosis factor (TNF)-alpha on the pro-inflammatory activation of human primary bronchial epithelial cells, was investigated. (PMID:20301193)
• IL-27 induced by mycobacterium tuberculosis infection in human macrophages opposed IFN-gamma production by antagonizing IL-18 activity. (PMID:20375623)
• IL-27 may regulate the expression of Mac-1, fMLP-R and IL-1beta in human neutrophils through p38 MAPK and PI3K signal pathways. (PMID:20416175)
• roles in activation of eosinophils and allergic responses (PMID:20435369)
• IL-27 p28 gene transcription is activated by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1 (PMID:20435892)
• This article reviews current understanding of the role of IL-27 in CD8+ T cell functions and generation of Cytotoxic T lymphocytes. (PMID:20454646)
• Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes (PMID:20519510)
• Significantly higher plasma concentration of IL-27 was found in rheumatoid arthritis patients (PMID:20604932)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Il27	ENSMUSG00000044701
rattus_norvegicus	Il27	ENSRNOG00000019170

Protein

Protein identifiers

Interleukin-27 subunit alpha — Q8NEV9 (reviewed: Q8NEV9)

Alternative names: Interleukin-30, p28

All UniProt accessions (2): Q8NEV9, H3BQY2

UniProt curated annotations — full annotation on UniProt →

Function. Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of pro-inflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 also has an effect on cytokine production, it suppresses pro-inflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication.

Subunit / interactions. Heterodimer with EBI3; not disulfide-linked. This heterodimer is known as interleukin IL-27.

Subcellular location. Secreted.

Tissue specificity. Expressed in monocytes and in placenta.

Post-translational modifications. O-glycosylated.

Induction. Transiently induced by bacterial lipopolysaccharides (LPS) stimulation in monocytes.

Similarity. Belongs to the IL-6 superfamily.

RefSeq proteins (1): NP_663634* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009079	4_helix_cytokine-like_core	Homologous_superfamily
IPR026207	IL-27_alpha	Family

UniProt features (16 total): helix 9, strand 2, sequence variant 2, signal peptide 1, chain 1, turn 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
7ZXK	X-RAY DIFFRACTION	2.2
8XWY	X-RAY DIFFRACTION	3.4
7U7N	ELECTRON MICROSCOPY	3.47
8D85	ELECTRON MICROSCOPY	3.81

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NEV9-F1	76.49	0.35

Antibody-complex structures (SAbDab): 1 — 7ZXK

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9020956	Interleukin-27 signaling

MSigDB gene sets: 142 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, GOBP_REGULATION_OF_CELL_ACTIVATION, CREL_01, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_ALPHA_BETA_T_CELL_ACTIVATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOBP_RESPONSE_TO_PEPTIDE, GOBP_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_ALPHA_BETA_T_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOCC_CELL_SURFACE, AREB6_01

GO Biological Process (12): positive regulation of defense response to virus by host (GO:0002230), inflammatory response (GO:0006954), positive regulation of type II interferon production (GO:0032729), regulation of T cell proliferation (GO:0042129), innate immune response (GO:0045087), regulation of T-helper 1 cell differentiation (GO:0045625), response to Gram-positive bacterium (GO:0140459), immune system process (GO:0002376), signal transduction (GO:0007165), response to bacterium (GO:0009617), regulation of defense response to virus (GO:0050688), regulation of T cell activation (GO:0050863)

GO Molecular Function (4): signaling receptor binding (GO:0005102), cytokine activity (GO:0005125), interleukin-27 receptor binding (GO:0045523), protein binding (GO:0005515)

GO Cellular Component (5): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), endoplasmic reticulum lumen (GO:0005788), cytosol (GO:0005829), cell surface (GO:0009986)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Interleukin-12 family signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of defense response to virus by host	1
defense response	1
positive regulation of cytokine production	1
type II interferon production	1
regulation of type II interferon production	1
T cell proliferation	1
regulation of lymphocyte proliferation	1
regulation of T cell activation	1
immune response	1
defense response to symbiont	1
regulation of immune effector process	1
regulation of T-helper 1 type immune response	1
T-helper 1 cell differentiation	1
regulation of T-helper cell differentiation	1
response to bacterium	1
biological_process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
response to other organism	1
regulation of response to biotic stimulus	1
regulation of defense response	1
regulation of response to external stimulus	1
defense response to virus	1
T cell activation	1
regulation of lymphocyte activation	1
protein binding	1
receptor ligand activity	1
cytokine receptor binding	1
binding	1
endoplasmic reticulum	1
intracellular organelle lumen	1
cytoplasm	1

Protein interactions and networks

STRING

1178 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL27	EBI3	Q14213	994
IL27	IL27RA	Q6UWB1	982
IL27	IL12RB2	Q99665	805
IL27	IL23A	Q9NPF7	773
IL27	CRLF1	O75462	766
IL27	IL12RB1	P42701	739
IL27	TBX21	Q9UL17	709
IL27	STAT1	P42224	704
IL27	IL17A	Q16552	681
IL27	IFNG	P01579	673
IL27	IL6	P05231	670
IL27	IL6ST	P40189	653
IL27	CD4	P01730	630
IL27	STAT3	P40763	630
IL27	IL6R	P08887	627

IntAct

9 interactions, top by confidence:

A	B	Type	Score
IL27RA	IL6ST	psi-mi:“MI:0914”(association)	0.590
IL27RA	IL6ST	psi-mi:“MI:0915”(physical association)	0.590
IL27	EBI3	psi-mi:“MI:0915”(physical association)	0.400
IL27	CRLF1	psi-mi:“MI:0915”(physical association)	0.400
WIF1	SMCHD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): IL27 (Affinity Capture-Western), EBI3 (Affinity Capture-Western), IL27RA (Affinity Capture-Western), IL27 (Affinity Capture-Western), IL27 (Affinity Capture-MS), S100P (Reconstituted Complex), S100A6 (Reconstituted Complex)

ESM2 similar proteins: A0A140LIA7, A0A1B0GTL2, A2VDX9, A3FFS8, A6NCS6, A8MVW0, K9M1U5, O43541, P01588, P03971, P03972, P07321, P07865, P0C7N4, P0DPE3, P13725, P27106, P29676, P33707, P33708, P33709, P48617, P49000, P49157, P53346, P79295, Q02011, Q0Z956, Q16619, Q1HCM0, Q28513, Q29RM6, Q5BLP8, Q5S1V9, Q60753, Q63086, Q65Z15, Q6H8S9, Q6H8T0, Q6H8T1

Diamond homologs: Q5S1V9, Q8K3I6, Q8NEV9

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
IL27	up-regulates	IL27RA	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	31
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1073956	NC_000016.9:g.(?28488827)(28950294_?)del	Pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1534 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:28503932:G:C	S50R	0.991
16:28503932:G:T	S50R	0.991
16:28503934:T:G	S50R	0.991
16:28503878:A:C	F68L	0.976
16:28503878:A:T	F68L	0.976
16:28503880:A:G	F68L	0.976
16:28501979:G:C	F153L	0.968
16:28501979:G:T	F153L	0.968
16:28501981:A:G	F153L	0.968
16:28503709:A:G	W97R	0.968
16:28503709:A:T	W97R	0.968
16:28501998:A:G	L147P	0.965
16:28503879:A:C	F68C	0.965
16:28502007:A:G	L144P	0.959
16:28503707:C:A	W97C	0.955
16:28503707:C:G	W97C	0.955
16:28503879:A:G	F68S	0.955
16:28503941:G:C	F47L	0.953
16:28503941:G:T	F47L	0.953
16:28503943:A:G	F47L	0.953
16:28502090:G:C	F116L	0.948
16:28502090:G:T	F116L	0.948
16:28502092:A:G	F116L	0.948
16:28499792:C:A	W197C	0.944
16:28499792:C:G	W197C	0.944
16:28503912:A:G	L57P	0.944
16:28503921:G:T	A54D	0.936
16:28503942:A:G	F47S	0.932
16:28499794:A:G	W197R	0.927
16:28499794:A:T	W197R	0.927

dbSNP variants (sampled 300 via entrez): RS1000325951 (16:28503889 C>A,T), RS1000834978 (16:28504243 C>G,T), RS1001569616 (16:28500176 G>A), RS1002292096 (16:28504547 A>G), RS1002379128 (16:28503172 G>A), RS1002838477 (16:28501533 C>A,T), RS1002966522 (16:28507200 A>G), RS1002999171 (16:28507017 C>T), RS1004210272 (16:28504378 T>TGA), RS1004266429 (16:28502127 T>C,G), RS1004413565 (16:28501626 C>T), RS1004493465 (16:28507885 C>T), RS1004854631 (16:28506365 G>A), RS1005135910 (16:28502868 G>C,T), RS1006093024 (16:28502983 C>A,T)

Disease associations

OMIM: gene MIM:608273 | disease phenotypes: MIM:256730

GenCC curated gene-disease

Mondo (1): neuronal ceroid lipofuscinosis (MONDO:0016295)

Orphanet (2): Neuronal ceroid lipofuscinosis (Orphanet:216), OBSOLETE: Infantile neuronal ceroid lipofuscinosis (Orphanet:79263)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs8049439	ATXN2L, IL27, NPIPB8		0.00	0

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
titanium dioxide	affects expression, increases secretion	2
Benzo(a)pyrene	decreases expression, increases methylation	2
Lipopolysaccharides	decreases reaction, increases expression	2
fluorene-9-bisphenol	decreases expression	1
Asian ginseng	affects cotreatment, decreases expression	1
TL8-506	affects cotreatment, increases expression, increases secretion	1
triphenyl phosphate	affects expression	1
nickel chloride	increases expression	1
perfluorooctanoic acid	decreases expression	1
nickel sulfate	decreases reaction, increases expression, increases reaction, increases secretion, affects reaction	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
titanium nickelide	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
SB 203580	decreases reaction, increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
BAY 11-7085	decreases reaction, increases expression	1
perfluorohexanesulfonic acid	decreases expression	1
Janus Kinase Inhibitors	increases secretion, decreases reaction	1
Diethylhexyl Phthalate	affects cotreatment, decreases expression, increases expression	1
Poly I-C	affects cotreatment, increases secretion	1
Silicon Dioxide	decreases expression	1
Valproic Acid	increases methylation	1
Sodium Selenite	increases expression	1
Okadaic Acid	decreases expression	1
Simvastatin	affects reaction, decreases expression, decreases secretion, increases expression, increases secretion	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8IE	Abcam HCT 116 IL27 KO	Cancer cell line	Male
CVCL_B8XC	Abcam MCF-7 IL27 KO	Cancer cell line	Female
CVCL_B9KN	Abcam A-549 IL27 KO	Cancer cell line	Male

Clinical trials (associated diseases)

7 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00337636	PHASE1	COMPLETED	Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)
NCT01238315	PHASE1	WITHDRAWN	Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis
NCT07582484	PHASE1/PHASE2	NOT_YET_RECRUITING	Gene Therapy Trial for CLN6 Batten Disease
NCT01873924	Not specified	RECRUITING	Clinical and Neuropsychological Investigations in Batten Disease
NCT01966757	Not specified	COMPLETED	Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities
NCT04613089	Not specified	RECRUITING	Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database
NCT06844877	Not specified	RECRUITING	Italian NCL Registry: a Registry for NCL as an Integration Tool for Future Therapeutic Strategies